Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data.
Liang-Liang DingF WenH WangD-H WangQ LiuY-X MoX TanMei QiuJ-X HuPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2020)
Different effective drugs should be used to prevent fragility fractures according to PMW with or without PVF, and romosozumab is the only one which can reduce clinical and vertebral fractures in both of the two populations. PTH and abaloparatide are less tolerated than placebo whereas the eight other drugs assessed in the study have the same tolerability as placebo.